Veeva Systems and Sarah Cannon Partner to Accelerate Cancer Clinical Trials

Veeva Systems Inc. (NYSE:VEEV) is one of the top 10 healthcare AI stocks to buy according to hedge funds.

Veeva Systems and Sarah Cannon Partner to Accelerate Cancer Clinical Trials

A team of IT experts monitoring a network of computers managing the medical content and communications.

Veeva Systems Inc. (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) announced a strategic collaboration aimed at advancing oncology clinical trials across more than 200 research sites. Through this partnership, SCRI will implement Veeva’s Clinical Platform to unify its contract research and site operations on a single, cloud-based infrastructure. The move is expected to streamline workflows, reduce startup delays, and enhance coordination between clinical teams, ultimately accelerating the delivery of novel cancer therapies to patients.

According to Yazhene Krishnaraj, Chief Information and Digital Officer at SCRI, the platform will empower the institute’s teams to operate with greater precision and speed. Jim Reilly, President of Veeva Development Cloud, noted the collaboration is a “first-of-its-kind” and will set a new benchmark for clinical trial execution and site engagement. The initiative reflects both organizations’ commitment to improving trial efficiency at scale. The collaboration not only enhances SCRI’s operational capacity but also reinforces Veeva’s growing role in transforming clinical research through intelligent, AI-powered solutions.

Veeva’s Clinical Platform includes tools such as electronic data capture, clinical trial management, regulatory document tracking, and remote site monitoring—all integrated into one system. It also incorporates artificial intelligence and machine learning to identify trial risks, predict site performance, and flag data anomalies before they disrupt studies. These AI capabilities solidify Veeva’s position as a key player in healthcare technology, helping research organizations make faster, data-driven decisions.

While we acknowledge the potential of VEEV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VEEV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now.

Disclosure: None.